📰 Forward Pharma News
Page 4 - Forward Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Forward Pharma. Real-time updates on events, politics, business and more.
March 18, 2022
StockNews.com began coverage on shares of Forward Pharma A/S (NASDAQ:FWP – Get Rating) in a report released on Friday. The firm set a “sell” rating on the biotechnology company’s stock. Forward Pharma A/S stock opened at $5.40 on Friday. Forward Pharma A/S has a 1-year low of $5.05 and a 1-year high of $20.31. The […]
March 5, 2022
StockNews.com started coverage on shares of Forward Pharma A/S (NASDAQ:FWP – Get Rating) in a report published on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock. Shares of FWP opened at $5.38 on Wednesday. Forward Pharma A/S has a 12 month low of $5.05 and a 12 month high of […]
October 13, 2021
/PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent...
April 14, 2021
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020 Forward Pharma A/S Hawthorne, New York, UNITED STATES COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 wa...
February 12, 2021
Editas Medicine James Mullen takes over as CEO from Feb. 15. Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon—later snapped up by Thermo Fisher—and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in ...
February 11, 2021
Dewpoint Therapeutics Appoints Joel Sendek as Chief Financial Officer - Sendek adds 30 years experience in biotechnology leadership News provided by Share this article Share this article BOSTON, Feb. 11, 2021 /PRNewswire/ -- Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer and Treasurer. "As we accelerate our growth plans, Joels financial expertise and leadership in fundraising and corporate finance for both p...
December 11, 2020
In a recent decision, Ixchel Pharma, LLC v. Biogen, Inc., the Supreme Court of California opened the door for some restrictive covenants between commercial enterprises, but it left...